Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Myeloma XI study: Quadruplet regimen for transplant eligible patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.12.18
Views: 771

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Dr Charlotte Pawlyn speaks to ecancer at ASH 2018 about the results of the Myeloma XI study.

The work being presented was focused on results from the comparison between a quadruplet regimen comprising of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD/CRD) induction therapy for transplant eligible patients.

Dr Pawlyn explains that the results showed that the quadruplet led to deeper responses and prolonged progression free survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation